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A B S T R A C T
Social isolation stress (SIS) as a type of chronic stress could induce depressive- and anxiety-like behaviors. Our
study evaluates the role of opioid system on negative behavioral impacts of SIS in male NMRI mice. We in-
vestigated eﬀects of morphine, a nonselective opioid receptor (OR) agonist, naltrexone (NLX), an OR antagonist,
naltrindole (NLT), a delta opioid receptor (DOR) antagonist, SNC80, a DOR agonist, U-69593, a kappa opioid
receptor (KOR) agonist, nor-Binaltorphimine, a selective KOR antagonist and cyprodime hydrochloride a se-
lective mu opioid receptor (MOR) antagonist on depressive- and anxiety-like behaviors. Using RT-PCR we
evaluated ORs gene expression in mice brain. Our ﬁndings showed that SIS induced anxiety- and depressive-like
behavior in the forced swimming test, open ﬁeld test, splash test and hole-board test. Moreover, administration
of SNC-80 signiﬁcantly mitigated anxiety- and depressive-like behaviors. NLT decreased grooming-activity in the
splash test. Excitingly, administration of agents aﬀecting KOR failed to alter the negative eﬀects of SIS. RT-PCR
demonstrated that MOR and KOR gene expression decreased in socially isolated mice; however, SIS did not aﬀect
DORs expression. Our ﬁndings suggest that SIS at least in part, probably via altering endogenous opioids par-
ticularly MORs and KORs but not DORs mediated negative impacts on behavior; also, it could be concluded that
DORs might be considered as a novel target for studying depression and anxiety.
1. Introduction
Social isolation stress (SIS) is considered as a valid animal paradigm
to study the eﬀects of chronic early life stress on later behaviors [1–3].
Clinical and preclinical studies have shown that experiencing early-life
stresses could profoundly aﬀect mood and behavior in the adulthood
[4–7]. Social isolation stress is a type of chronic stress that could in-
crease seizure susceptibility, depressive- and anxiety-like behaviors
[8–11]. Few molecular pathways have been proposed to be involved in
these outcomes, although the exact mechanisms responsible for adverse
eﬀects of SIS are still unclear. Past studies have suggested that SIS could
induce neurochemical changes in the brain [12–17]. However, the
involving of opioid system in depression- and anxiety-like behavior
following SIS is not clearly investigated.
It has been suggested that opioid system is involved in various
pathways including pain, depression, anxiety, memory, addiction and
seizure [18–22]. Previous studies have demonstrated that opioid system
regulates the natural activities such as sexual and social behaviors
[23–25]. Endogenous opioids interact with opioid receptors including
mu- (MOR), delta (DOR) and kappa (KOR) -opioid receptors [26]. Re-
cently, it has been determined that stress could impact on opioid system
by increasing the levels of dynorphin as an endogenous KOR ligand
[27]. Animal studies revealed that lack of opioid receptors induced
depressive- and anxiogenic-like behaviors [28].
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The aim of present study is to investigate the role of opioid system in
depression- and anxiety-like behaviors in a mouse model of SIS. For
reaching this goal, we investigated the eﬀect of morphine, cyprodime
hydrochloride (CYP) naltrexone (NLX), naltrindole (NLT), U-69593,
nor-binaltorphimine (nor-BNI), and SNC80 on depressive- and anxiety-
like behaviors in socially isolated animals. Also, we evaluated the gene
expression of each opioid receptor using RT-PCR method in the hip-
pocampus and amygdala samples.
2. Materials and methods
2.1. Animals and housing conditions
Male NMRI mice aged 21–25 days and weighing 10–12 g were used.
Animals were housed in two diﬀerent conditions including social con-
dition (SC) and isolated condition (IC). All animals were kept under
standard laboratory conditions i.e. temperature: 22 ± 2 °C, humidity:
50 ± 10%, 12-h light–dark cycle, and ad-libitum access to food and
water for a period of 5 weeks. Socially conditioned mice were placed in
plexiglas boxes (25 cm×25 cm×15 cm) (6 mice per cage) and IC
animals were placed individually in Plexiglas boxes (24 cm×17
cm×12 cm) [8,12]. In order to diminish handling and social interac-
tion cages of IC animals were cleaned weekly by the same experi-
menter. All experiments were carried out between 10:00 a.m. and 02:00
p.m. Each mouse was used only once for each test. Each trial group
contained 6–8 animals. All tests were performed in accordance with
National Institutes of Health (NIH) Guide for the Care and Use of La-
boratory Animals (NIH publication #80-23) and institutional guidelines
for animal care and use.
2.2. Drugs
Morphine sulfate (non-selective opioid receptor agonist, 1 and
5mg/kg), Naltrexone or NLX (non-selective opioid receptors antago-
nist), (+)-4-(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-
methoxybenzyl80-N,N-diethylbenzamide or SNC80 (selective DOR
agonist), Naltrindole or NLT (selective DOR antagonist), U-69593 (se-
lective KORs agonist), nor-Binaltorphimine (nor-BNI, selective KORs
antagonist), Cyprodime hydrochloride (CYP, a selective MOR antago-
nist) and Pentylenetetrazole (PTZ) were purchased from Sigma (Sigma,
St Louis, MO, USA).
2.3. Experiment design and treatments
In the ﬁrst step, behavioral tests including forced swimming test
(FST), open-ﬁeld test (OFT) and the splash test were used to evaluate
anxiety- and depressive-like behaviors in both social and isolated con-
dition animals. On the next step, the possible eﬀects of opioid receptor
agonists/antagonists on socially isolated mice were assessed using
above-mentioned tasks. In this regard, mice (IC and SC) were treated
with morphine (1 and 5mg/kg, i.p. 30min prior to tests), naltrexone
(3mg/kg, i.p. 30min prior to test), nor- nor-Binaltorphimine (5mg/kg,
i.p. 30min prior to test) Cyprodime hydrochloride (3 and 10mg/kg, i.p.
60 min prior to test), SNC80 (1mg/kg, i.p. 60min before tests), nal-
trindole (1 mg/kg, i.p. 30min before tests), and U-69593 (3mg/kg
subcutaneously, 15min prior to test). Naltrindole, morphine and nal-
trexone were dissolved in saline and injected intraperitoneally (i.p.)
30 min before the tests in a constant volume of 5ml/kg body weight
[29–34]. SNC80 and nor-Binaltorphimine was dissolved in di-
methylsulfoxide (DMSO; 5%) and diluted in physiological saline solu-
tion [35,36]. Also, cyprodime hydrochloride was dissolved in 1%
ethanol and U-69593 (3mg/kg) was suspended in 25% propylene
glycol [33,37,38]. To exclude the possible impact of solvents, DMSO,
propylene glycol and saline were also used as vehicles at constant vo-
lume of 5ml/kg. The doses and time of drug administrations were
chosen based on our pilot study and also above-mentioned published
reports. In the ﬁnal step, after removing hippocampus and amygdala
from the brain, we evaluated the gene expression of opioid receptors
including MORs, KORs and DORs.
2.4. Open-ﬁeld test (OFT)
Open-ﬁeld test was done just before the FST to assess the locomotor
activity of animals [39,40]. OFT was used to exclude the possibility that
changes in immobility time are not the result of modiﬁcations in motor
activity and also to interpret the locomotor activity in response to SIS
[41]. The apparatus of OFT was made of white opaque plexiglas
(50 cm×50 cm×30 cm) and was softly illuminated. Each mouse was
placed gently on the central area (30 cm×30 cm) and behaviors were
documented by a camera in a 5min period and were analyzed by
Ethovision software version 8 (Noldus, Netherlands). The apparatus
was cleaned with 70% ethanol after each experiment. The distance
moved (horizontal activity) and the numbers of rearing (vertical ac-
tivity) and time spent in central zone (central activity) were evaluated.
2.5. Forced swimming test (FST)
The FST was conducted based on previously described method
[42–44]. Mice were separately placed in an open cylinder-shaped bottle
(diameter 10 cm, height 25 cm), containing 19 cm water (23 ± 1 °C).
Mice were permitted to swim for 6min and the period of immobility
was recorded during the last 4 min of the test. Each mouse was judged
to be immobile when it terminated struggling and stayed ﬂoating im-
mobile, making only those activities necessary to keep its head above
the water.
2.6. Splash test
In order to evaluate the self-care and motivational behaviors splash
test was performed. In this paradigm, grooming activity time, as an
indirect measure of palatable solution intake, was evaluated. 10% su-
crose solution was sprayed on the dorsal coat of animals. The total
grooming activity time was recorded during 5min after the sucrose
vaporization [10,45]. Grooming activity consists of nose/face
grooming, head washing and body grooming.
2.7. Hole board test (HBT)
Hole-board test is considered as a reliable trial to assess the anxiety-
like behaviors in the rodents [46]. The apparatus was made of a white
Plexiglas square (50 cm×50 cm) with 16 equally sized holes (3 cm in
diameter) and was located 50 cm above the ﬂoor. Mice were placed in
the center of the board, and the number of head-dips was calculated in a
5-min period by an experimenter.
2.8. Real-time RT-PCR analysis for hippocampus opioid receptor genes
Hippocampus and amygdala were removed and immediately frozen
on dry ice, and then stored at −80 °C. In the ﬁrst step total RNA was
extracted from hippocampi and amygdala using Trizol reagent
(Invitrogen, Cergy Pontoise, France). Alterations in the mRNA levels of
genes were determined using qRT-PCR after the reverse transcription of
1 μg of RNA from each sample using PrimeScript RT reagent kit (Takara
Bio Inc., Otsu, Japan). qRT-PCR was completed on a light cycler device
(Roche Diagnostics, Mannheim, Germany) using SYBR Premix Ex Taq
technology (Takara Bio). Sequences of primers are shown in Table 1.
Thermal cycling conditions included an initial activation step for 30 s at
95 °C afterwards 45 cycles as well as a denaturation step for 5 s at 95 °C
and a combined annealing/extension step for 20 s at 60 °C. Melting
curve analysis was performed to certify whether all primers yielded a
single PCR product. Hypoxanthine phosphoribosyl transferase1
(Hprt1), was considered as a normalizer and fold changes in expression
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of each target mRNA relative to Hprt1 was calculated based on 2−ΔΔCt
relative expression formula as described previously [6,47,48]
2.9. Statistical analysis
Comparisons between the groups were assessed using t-test and one-
way ANOVA followed by Tukey’s post hoc test using GraphPad Prism 7
software (San Diego, CA, USA). P values less than 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. Eﬀects of SIS on depressive- and anxiety-like behaviors
Results obtained from the t-test analysis revealed that SIS sig-
niﬁcantly increased immobility time in the FST (t=10.17, df=14,
P < 0.001, Fig. 1A) and also signiﬁcantly decreased grooming activity
time in the splash test (t=9.355, df=14, P < 0.001, Fig. 1B) in
comparison with SC animals. In the OFT, IC animals showed higher
locomotor activity, considering total distance moved (t=3.594,
df=14, P < 0.01, Fig. 1C) and number of rearings (t=4.248, df=14,
P < 0.001, Fig. 1D) compared to SC animals. Also, analysis showed
that time spent in the central zone of OFT in socially isolated animals
signiﬁcantly decreased in comparison to normal condition (t=3.219,
df=10, P < 0.01, Fig. 1E). t-test analysis on results of the HBT
showed an anxiety-like behavior in IC mice (t=4.213, df=14,
P < 0.001, Fig. 1FE) when compared to SC animals.
3.2. Eﬀect of opioid receptors agonists and antagonists on depressive- and
anxiety-like behaviors
In this step, we tried to investigate the role of opioid system in the
pathophysiology of depressive- and anxiety-like behavior following SIS
paradigm. One-way ANOVA analysis demonstrated that administration
of opioid receptor agonists and antagonists could impact the immobility
time in the FST (F (9, 61)= 0.7709, P < 0.001, Fig. 2 A). Tukey’s
analysis showed that administration of higher dose of morphine (5mg/
kg, P< 0.05), U-69593 (3mg/kg, P< 0.01), higher dose of CYP
(10mg/kg, P< 0.05), and nor-BNI (5mg/kg, P< 0.05) in SC animals,
signiﬁcantly increased immobility time in the FST in comparison to
vehicle-treated SC mice. On the other hand, administration of these
drugs in IC animals showed that treatment with SNC80 signiﬁcantly
decreased immobility time when compared with vehicle-treated coun-
terpart (P < 0.001, Fig. 2B).
In the splash test, one-way ANOVA analysis revealed that admin-
istration of opioid receptor agonists and antagonists could aﬀect
grooming activity time in both IC (F (9, 70)= 2.59, P < 0.001, Fig2C)
and SC animals (F (9, 70)= 1.277, P < 0.001, Fig2D) compared to
vehicle-treated counterparts. Tukey’s analysis showed that administra-
tion of morphine at higher dose (5mg/kg, P< 0.01) and U-69593
(3mg/kg, P< 0.05) in SC mice, signiﬁcantly decreased grooming time,
however, injection of NLX at 3mg/kg and CYP at 10mg/kg increased
the grooming time (P< 0.05) when compared to vehicle-treated ani-
mals. Also in IC animals, post Tukey’s analysis showed that injection of
NLT at 1mg/kg signiﬁcantly decreased (P< 0.05) and SNC80 (1mg/
kg) increased (P< 0.01) grooming activity time compared to vehicle-
treated animals.
One-way ANOVA analysis showed that administration of morphine
(1 and 3mg/kg), NLX (3mg/kg), NLT (1mg/kg), and SNC80 (1mg/kg)
could not aﬀect the distance moved at the OFT in both IC (F (9,
70)= 1.02, P > 0.05, Fig. 2 F) and SC animals (F (9, 70)= 1.257,
P > 0.05, Fig. 2E). In addition, one-way ANOVA failed to show any
signiﬁcant diﬀerences between administrations of these drugs in the
number of rearings in both IC (F (9, 70)= 0.3355, P > 0.05, Fig2H)
and SC mice (F (9, 70)= 0.7794, P > 0.05, Fig. 2G) when compared to
vehicle-treat mice.
In the ﬁnal step we evaluated the anxiety-like behavior in both IC
and SC animals after administration of all the mentioned drugs in both
HBT and OFT (time spent in the central zone). Result obtained from the
one-way ANOVA analysis showed that none of the administrated drugs
Table 1
Primers for RT-PCR.
Gene name Primers (Forward and reverse)
Opioid Receptor, mu 1 F: GAGCCACAGCCTGTGCCCT
R: CGTGCTAGTGGCTAAGGCATC
Opioid Receptor, Kappa 1 F: CCTGGCATCATCTGTTGGTA
R: GGAAACTGCAAGGAGCATTC
Opioid Receptor, Delta 1 F: GCTCGTCATGTTTGGCATC
R: AAGTACTTGGCGCTCTGGAA
Hprt1 F:TGCTCGAGATGTGATGAAGG
R: AAGCAGATGGCCACAGAACT
Fig. 1. Eﬀects of social isolation stress (IC) on behavioral despair in immobility time of the FST (A), self-care behavior in the Splash test (B), locomotor activity in the
OFT (C and D), and anxiety-like behavior in the OFT (time spent in central zone) and HBT (E and F). Values are expressed as the mean ± S.E.M. from 6 to 8 animals
and were analyzed using t-test. *** P < 0.001 compared to SC animals.
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including morphine (1 and 3mg/kg), U-69893 (3mg/kg), NLT (1mg/
kg), NLX (3mg/kg), and SNC80 (1mg/kg), nor-BNI (5mg/kg) and CYP
(3 and 10mg/kg) had any eﬀect in the hole-broad results of SC animals
compared with vehicle-treatment (F (9, 70)= 0.4385, P > 0.05,
Fig2K). Also, injection of these drugs in IC animals showed no sig-
niﬁcant eﬀect except for SNC80 (F (9, 70)= 0.6545, P > 0.05, Fig2L).
Post analysis revealed that SNC80 led to anxiolytic-like behavior in the
Hole-broad test (P < 0.001) by increasing the number of head dips in
comparison with vehicle-treated IC animals. Similar results were
documented from IC (F (9, 70)=1.447, P < 0.001, Fig2I) and SC (F (8,
63)= 0.9091, P > 0.05, Fig2I) animals in the time spent in the central
zone (OFT). Post hoc analysis showed that SNC80 signiﬁcantly de-
creased anxiogenic-like behavior in IC mice in comparison with vehicle-
treated animals (P< 0.001).
3.3. Gene expression of opioid receptors
Our results demonstrated the signiﬁcant diﬀerences in gene ex-
pression of opioid receptors in hippocampus (F (5, 24)= 18.73,
P < 0.001, Fig. 3A) and amygdala (F (5, 24)= 15.01, P < 0.001,
Fig. 3B) between IC and SC animals in two-way ANOVA analysis. Tu-
key’s analysis showed that SIS could decrease gene expression of MORs
(P < 0.001) and KORs (P< 0.01) compared to SC animals in hippo-
campus. Also, data obtained from amygdala showed that MORs
(P< 0.001) and KORs (P< 0.05) gene expression signiﬁcantly de-
creased in socially isolated animals. However, there is no signiﬁcant
diﬀerence in gene expression of DORs neither in hippocampus nor
amygdala between IC and SC animals.
4. Discussion
In the current study, we examined the possible role of the opioid
system on anxiety- and depressive- like behaviors in SIS paradigm.
Although SIS and opioid system have been investigated previously, the
relation between the therapeutic eﬀects of this system on behavioral
despair induced by SIS have not been documented well. In this regard,
we aimed to assess whether opioid receptors could be considered as a
potential target for treatment of the adverse eﬀects of SIS. Also, the
gene expression of opioid receptors was evaluated to illuminate the
impact of opioid system. Our results showed that administration of
delta opioid agonist (SNC80) attenuated immobility time in FST and
increased the time spent in central zone and also the numbers of head-
dips in OFT and HBT in isolated condition group. In consistency with
our behavioral experiments, we found that gene expression of KORs and
MORs signiﬁcantly decreased after social isolation stress in hippo-
campus and amygdala. This is probably caused by increase in en-
dogenous Kappa and Mu agonist tone. In contrast with KORs and MORs
gene expression, DORs gene expression did not alter signiﬁcantly nei-
ther in hippocampus nor amygdala.
A large body of evidence and our past studies showed that SIS could
induce anxiety- and depressive-like behavior in some behavioral tasks
[10,49] such as the hole-board test (HBT), the open ﬂied test (OFT),
forced swimming test (FST) and the splash test. In line with afore-
mentioned studies, we observed that IC animals showed increased im-
mobility time in the FST and decreased grooming activity time in the
Splash test. Also, increased moving distance and number of rearings in
addition to the decreased time spent in central zone at the OFT revealed
Fig. 2. Eﬀects of morphine (1 and 5mg/kg), U-69593 (3mg/kg), naltrindole (NLT, 1mg/kg), naltrexone (NLX, 3mg/kg), nor-BNI (5mg/kg), CYP (3 and 10mg/kg)
and SNC-80 (1mg/kg) on socially isolated (IC) and normal (SC) animals in some behavioral tasks including FST (A and B), Splash test (C and D), OFT (E, F, G, H, I and
J) and HBT (K and L). Values are expressed as the mean ± S.E.M. from 6 to 8 animals and were analyzed using one-way ANOVA followed by Tukey’s post hoc test.
*P< 0.05, **P< 0.01, and ***P < 0.001, drug-treated animals from each group were compared to corresponding vehicle-treated animals.
A. Haj-Mirzaian et al. Biomedicine & Pharmacotherapy 109 (2019) 938–944
941
higher locomotor activity in IC mice. Also consistent with above-men-
tioned studies, we demonstrated that SIS could induce anxiety-like
behavior in the HBT.
The opioid system consists of distributed neurons that produce en-
dogenous opioids including enkephalins, dynorphins and β-endorphins
[50]. Endogenous opioids are neurotransmitters and neuromodulators
of mu, delta and kappa opioid receptors [51]. Although, the role of
opioid system in behavioral functions has been previously investigated,
only scarce controversial ﬁndings are available in this regard. However,
further animal studies showed that this inconsistency could be due to
various factors including chronic or acute usage of opioid agonists/
antagonists, their dosage, type of targeted receptors (Mu, Kappa, or
Delta), species, and etc. In this regard, Poznanski et al. showed that
chronic blockade of opioid system by naloxone (non-selective opioid
receptor antagonist) could induce anxiety- and depressive-like behavior
in rodents [52]. However, other study suggested that acute adminis-
tration of morphine (selective opioid receptor agonist) could led to
increased anxiety- and depressive-like behavior in animals similar to
chronic naloxone treatment [53]. Nonetheless, there is little informa-
tion on the relationship between chronic stressors such as SIS and
opioid system. Our results suggest that opioid system might be involved
in the adverse eﬀects of SIS. Hence, below we will discuss about the
potential associations of each opioid receptor with mood disorders in
details.
4.1. Kappa opioid receptor (KORs)
The role of KORs in pathophysiology of depression and anxiety is
not fully understood; however, several studies have shown that KOR
antagonists possess antidepressant-like eﬀect in behavioral tasks
[34,38,54–56]. Past studies revealed that activation of dynorphin/KOR
pathway in stress-related brain regions could have led to behavioral
disorders [57,58]. It has been shown that increase in the level of dy-
norphin following stress could reduce releasing of the dopamine
[5,59,60]. Previous studies demonstrated that dysregulation of meso-
limbic dopaminergic system may associate with depressive- like beha-
vior IC mice [61,62]. Likewise social isolation increases the accumbal
dynorphin/KOR function which is associated with alteration in nucleus
accumbens dopaminergic signaling pathway [5].
In this study, administration of U-69593 (as a selective KOR agonist)
in SC animals led to depressive-like behavior in both the FST (by in-
creasing the immobility time) and the splash test (by decreasing the
grooming activity time) but administration of nor-BNI (as a selective
KOR antagonist), exerted anti-depressant-like behavior in the FST.
Injection of U-69593 and Nor-BNI in SC mice failed to cause signiﬁcant
eﬀect in the hole-board test and the OFT. Interestingly, we observed
that nor-BNI did not possessed anti-anxiety and anti-depressive-like
behaviors in IC animals.
4.2. Delta opioid receptor (DORs)
It has been demonstrated that activation of DORs increase the re-
lease of norepinephrine and thus could mitigate depression and anxiety
[63,64]. Animal studies show that deletion of the DOR gene induces
anxiety-like behaviors [65]. Likewise, prior reports demonstrate that
administration of DOR antagonists increases anxiety-like behaviors
[66,67], while DORs agonists reduce the aforementioned behavioral
impairments [68,69]. According to previous studies, injection of en-
kephalinase inhibitors increases the level of enkephalins (as ligands of
DOR), leading to antidepressant eﬀects [70]. Broom et al., also revealed
that administration of SNC80, a DOR agonist, induces antidepressant-
like behavior in the FST [71]. In the present study, administration of
SNC80 (a selective DOR agonist) in SC animals did not aﬀect the FST,
OFT, splash test, and hole-broad test. However, in IC mice, SNC80 in-
duced anxiolytic- and antidepressant-like eﬀects. Also, injection of DOR
antagonist (naltrindole) in SC could not induce any eﬀect in all expri-
mental tasks. However, administration of naltrindole possessed de-
pressant-like eﬀect in the Splash test (not in the FST).
4.3. Mu opioid receptor (MORs)
MORs has a key role in reward system [59,72]. Studies showed that
MORs are involved in the pathophysiology of anxiety and depression
[73]. In this regard, it has been demonstrated that deletion of the MORs
gene could decrease anxiety- and depressive-like behaviors in animals
[74]. Controversially, some studies have indicated that activation of
MORs could result in antidepressant- and anxiolytic-like eﬀects [75]. In
this study, we used morphine (Ki: 14 for MORs, 538 and 1000 for KORs
and DORs [76], respectively) and cyprodime hydrochloride to evaluate
the role of MOR on behavioral despair induced by SIS. Administration
of morphine exerted depressant-like eﬀect in SC animals at dose of
5mg/kg in both the FST and the Splash test, while cyprodime hydro-
chloride at dose of 10mg /kg induced anti-depressant –like eﬀect in
both FST and splash test. However, injection of morphine and CYP
could not aﬀect any experimental tests in IC animals.
In the ﬁnal step, for clarifying the above results, we investigated the
gene expression of ORs in the hippocampus and amygdala. In this
study, we observed that gene expression of the KORs and MORs but not
DORs, signiﬁcantly decrease following SIS. Taken together these data
suggests that opioid receptors are involved in pathophysiology of an-
xiety- and depressive-like behavior induced by SIS. On the other hand,
intact DOR expression in addition to anti-depressant and anxiolytic-like
eﬀect of DORs agonist in socially isolated animals suggest that DORs
agonist could be used as a new and novel treatment to decrease SIS
consequences including anxiety and depression.
Although, evaluating of endogenous opioids could make our hy-
pothesis stronger, in the current study, the aforementioned evaluation
has been restricted due to our limitations. In this regard, this manu-
script recommends future studies to evaluate the activity of endogenous
opioid peptides in socially isolated animals for clarifying the role of
Fig. 3. Eﬀects of social isolation stress on gene expresion of DORs, MORs, and
KORs in both hippocampus (A) and amygdala (B). Values are expressed as the
mean ± S.E.M. from 4 animals and were analyzed using two-way ANOVA
followed by Tukey’s post hoc test. **P< 0.01, and ***P < 0.001 were com-
pare to social condition animals.
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opioid system in behavioral despair induced by SIS.
5. Conclusion
In this study, our results hypothesized that SIS could probably in-
crease endogenous opioids which may interact with MORs and KORs
but not DORs. Also, it could be concluded that DORs agonist might be a
novel target for treatment of depression and anxiety in SIS. Based on
our molecular study, intact DORs and probably its endogenous, in
contrast with other opioid receptors, suggested that targeting of DORs
could use as a novel treatment of behavioral despair induced by SIS.
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